IGM Biosciences Management
Management criteria checks 3/4
IGM Biosciences' CEO is Fred Schwarzer, appointed in Jul 2010, has a tenure of 13.75 years. total yearly compensation is $5.32M, comprised of 11.7% salary and 88.3% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $1.85M. The average tenure of the management team and the board of directors is 3 years and 5.7 years respectively.
Key information
Fred Schwarzer
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 11.7% |
| CEO tenure | 13.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20
We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Feb 08IGM Biosciences reports quick assets and provides business updates
Jan 13Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares
Dec 18IGM Bio prices upsized $200M public offering
Dec 09IGM Biosciences proposes public offering
Dec 07IGM Biosciences (IGMS) Investor Presentation - Slideshow
Nov 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$238m |
| Jun 30 2023 | n/a | n/a | -US$234m |
| Mar 31 2023 | n/a | n/a | -US$229m |
| Dec 31 2022 | US$5m | US$622k | -US$221m |
| Sep 30 2022 | n/a | n/a | -US$219m |
| Jun 30 2022 | n/a | n/a | -US$205m |
| Mar 31 2022 | n/a | n/a | -US$185m |
| Dec 31 2021 | US$10m | US$598k | -US$165m |
| Sep 30 2021 | n/a | n/a | -US$139m |
| Jun 30 2021 | n/a | n/a | -US$115m |
| Mar 31 2021 | n/a | n/a | -US$95m |
| Dec 31 2020 | US$5m | US$530k | -US$81m |
| Sep 30 2020 | n/a | n/a | -US$72m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$53m |
| Dec 31 2019 | US$757k | US$428k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$37m |
| Jun 30 2019 | n/a | n/a | -US$34m |
| Mar 31 2019 | n/a | n/a | -US$27m |
| Dec 31 2018 | US$519k | US$376k | -US$23m |
Compensation vs Market: Fred's total compensation ($USD5.32M) is above average for companies of similar size in the US market ($USD2.37M).
Compensation vs Earnings: Fred's compensation has been consistent with company performance over the past year.
CEO
Fred Schwarzer (70 yo)
13.8yrs
Tenure
US$5,316,460
Compensation
Mr. Fred M. Schwarzer, J.D., was a Founder of Charter Life Sciences, a venture capital firm specializing in life sciences investments, in 2003 and served as its Managing Partner from inception until August...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 13.8yrs | US$5.32m | 0.41% $ 1.8m | |
| Chief Scientific Officer | 11.7yrs | US$1.84m | 0.18% $ 798.5k | |
| Chief Medical Officer | 2.8yrs | US$1.83m | 0.038% $ 170.9k | |
| Chief Financial Officer | 5.3yrs | US$1.08m | 0.031% $ 140.4k | |
| Senior Vice President of Group Operations | 1.3yrs | no data | no data | |
| Senior VP | 2.1yrs | no data | 0.0020% $ 9.2k | |
| Senior Vice President of Legal Affairs | 3.3yrs | no data | no data | |
| Chief Human Resources Officer | 4.8yrs | no data | no data | |
| Senior Vice President of Immuno-Oncology | 2.7yrs | no data | no data | |
| Chief Business Officer | 3.1yrs | US$4.92m | 0.028% $ 125.6k | |
| Executive Vice President of Process Development & Manufacturing | 3yrs | no data | no data | |
| Head of Research & Autoimmunity | 2.5yrs | no data | no data |
3.0yrs
Average Tenure
59yo
Average Age
Experienced Management: IGMS's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 21.2yrs | US$5.32m | 0.41% $ 1.8m | |
| Independent Director | 3.3yrs | US$394.91k | 0.0038% $ 17.1k | |
| Independent Director | 5.3yrs | US$381.52k | 0.68% $ 3.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$369.35k | 0.0099% $ 45.1k | |
| Independent Director | 5.7yrs | US$369.35k | 0.14% $ 653.4k | |
| Independent Director | 5.7yrs | US$407.41k | 0.0034% $ 15.4k | |
| Independent Director | 5.7yrs | US$379.15k | 0.091% $ 411.2k | |
| Independent Director | 5.7yrs | US$439.91k | 0% $ 0 | |
| Director | less than a year | no data | 0.0025% $ 11.2k | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.7yrs
Average Tenure
54yo
Average Age
Experienced Board: IGMS's board of directors are considered experienced (5.7 years average tenure).